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Summary
Tumor vasculature is hyperpermeable to macromolecules compared to normal vasculature; however, the relationship
between tumor hyperpermeability and tumor progression is poorly understood. Here we show that a cell-permeable peptide
derived from caveolin-1, termed cavtratin, reduces microvascular hyperpermeability and delays tumor progression in mice.
These antipermeability and antitumor actions of cavtratin occur in the absence of direct cytostatic or antiangiogenic
effects. Cavtratin blocks microvascular permeability by inhibiting endothelial nitric oxide synthase (eNOS), as the antiperme-
ability and antitumor actions of cavtratin are markedly diminished in eNOS knockout mice. Our results support the concepts
that hyperpermeability of tumor blood vessels contributes to tumor progression and that blockade of eNOS may be exploited
as a novel target for antitumor therapy.
Introduction Recently, we reported that a cell-permeable peptide, con-
sisting of the homeodomain of the Drosophila transcription fac-
Vascular endothelial growth factor (VEGF) is a multifunctional cyto- tor antennapedia (AP or penetratin), coupled to a peptide de-
kine secreted by tumor cells and is thought to be responsible for rived from the eNOS inhibitory protein caveolin-1 (AP-Cav) was
the hyperpermeable state of tumor blood vessels (Carmeliet and able to selectively block endothelium-dependent relaxations
Collen, 2000; Dvorak et al., 1991; Matsumoto and Claesson-Welsh, and eNOS, but not inducible NOS (iNOS) mediated NO release
2001). VEGF binds to its cognate receptors and can activate the (Bucci et al., 2000). This peptide, now termed cavtratin (see
production of the free radical gas nitric oxide (NO) through the Supplemental Table S1 at http://www.cancercell.org/cgi/content/
enzyme endothelial nitric oxide synthase (eNOS) (Papapetropoulos full/4/1/31/DC1), when administered to mice markedly reduced
et al., 1997; Ziche et al., 1997). The stimulated release of NO is interstitial edema and microvascular leakage in the context of
central to the in vivo biological activity of VEGF in postnatal animals two models of subchronic inflammation but did not influence
since VEGF-driven vascular leakage and arteriogenesis/angiogen-
systemic hemodynamics (Bucci et al., 2000). In the presentesis are markedly reduced in eNOS-deficient mice (Fukumura et
study, we investigated whether cavtratin, by virtue of its abilityal., 2001; Murohara et al., 1998a). This increase in tumor vessel
to reduce interstitial edema, could influence vascular leakagepermeability is thought to contribute to the deposition of plasma
in tumors and impact tumor progression in mice.proteins, which may provide a provisional matrix for the inward
migration of fibroblasts and endothelial cells into tumors and am-
Results and Discussionplify the signals important for tumor growth. Although the increased
extravasation of macromolecules is an established property of
Since hyperpermeability has long been recognized as a hallmarktumor vessels (Dvorak et al., 1988), it has never been exploited
as a target for antitumor therapy. of tumor vasculature (Dvorak et al., 1988), we examined the
S I G N I F I C A N C E
The leakiness to plasma macromolecules has long been recognized as a trait of tumor microvasculature. The impact of this phenome-
non has not been exploited in the context of tumor growth and maintenance or for the development of novel therapies. Our study
shows that a selective inhibitor of nitric oxide-dependent vascular leakage, cavtratin, reduces plasma macromolecule extravasation
from tumor vasculature. This reduced tumor vessel permeability results in a significant inhibition of tumor growth in two mouse models.
Thus, cavtratin is a novel therapeutic modality that directly interferes with vessel permeability, a hallmark of tumor vasculature
necessary for tumor maintenance and growth in mice.
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Figure 1. Cavtratin reduces VEGF-induced and tumor vascular permeability
A: VEGF-mediated vascular leakage was monitored by intradermal injection of VEGF (30 ng) into the ear of CD-1 mice. Mice were treated with vehicle,
cavtratin, or AP-Cav-X (2.5 mg/kg i.p. each) for 45 min and were then anesthetized (ketamine/xylazine) for administration of Evans blue (via the left jugular
vein; 30 mg/kg) 1 min prior to VEGF (30 ng in 30 l) and saline (30 l) administration. VEGF and saline were each administered intradermally (for 30 min)
on the dorsal side of each ear. Ears were weighed prior to extraction of Evans blue with formamide and the content of Evans blue was determined
spectrophotometrically at 610 nm.
B: C57BL/6 mice bearing LLC tumors of 2500 mm3 were treated with vehicle, cavtratin (2.5 mg/kg; i.p.), or AP-Cav-X (2.5 mg/kg; i.p.) 1 hr before Evans blue
administration. Tumors were excised and Evans blue content was quantified spectrophotometrically.
C: Animals treated as in B, and in addition, FITC-dextran (400 kDa; i.v.) was administered to the mice (100 mg/kg) 1 min prior to tumor excision. One hundred
micrometer vibrotome sections were quantified for areas of Evans blue (TRITC/ rhodamine filter) and FITC-dextran fluorescence and expressed as ratios of
area of Evans blue to FITC-dextran. All graphs are represented as means  SEM and *p  0.05 versus CT and AP-Cav-X.
D: Representative images of Evans blue (red) and FITC-dextran (green) fluorescence of LLC tumors from cavtratin- and AP-Cav-X-treated mice. All graphs
are from at least five mice per group.
effects of cavtratin on vascular leakiness. VEGF is a prominent ever, in contradistinction to NOS inhibitors, cavtratin does not
affect systemic blood pressure or blood flow. Intravenous ad-cytokine responsible for the hyperpermeable state of tumor
vessels; thus we initially investigated the effects of cavtratin on ministration of cavtratin or AP-Cav-X (2.5 mg/kg, i.v. bolus) had
no effect on systemic blood pressure (81.8 3.2 mm Hg versusVEGF-driven vascular leakage in a modified Miles assay (Figure
1A). Intradermal administration of VEGF in the ear of CD-1 mice 83.6  4.1 mm Hg for cavtratin- and AP-Cav-X-treated mice,
respectively; n  7 mice per group) consistent with previousproduced a marked increase in Evans blue extravasation, which
is indicative of albumin and plasma protein leakage into the data (Bucci et al., 2000).
In order to determine if cavtratin treatment acutely reducedinterstitium (Murohara et al., 1998b). Treatment of mice with 2.5
mg/kg of cavtratin (administered i.p. 30 min prior to intradermal vascular permeability in the tumor vasculature, we monitored
the effects of cavtratin on the hyperpermeable state of the tumorVEGF) resulted in a significant inhibition of vascular leakage
compared to vehicle or AP-Cav-X (a scrambled control peptide vasculature. Lewis lung carcinoma (LLC) tumors inoculated sub-
cutaneously into C57BL/6 mice were allowed to grow to approx-administered at 2.5 mg/kg; Figure 1A) treated mice. This effect of
VEGF is largely dependent on NO release since VEGF-induced imately 2500 mm3, and animals were treated with either vehicle
or a single dose of cavtratin or AP-Cav-X (2.5 mg/kg of each).vascular leak is abrogated in eNOS-deficient mice or by treat-
ment of wild-type mice with NOS inhibitors, such as L-nitro Evans blue was then administrated to the mice (30 mg/kg, i.v.)
and the tumors were subsequently perfused with saline and thearginine methyl ester (L-NAME; Fukumura et al., 2001). How-
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amount of Evans blue extravasated into the tumor quantified. rate experiments with at least five mice per group. Histological
examination of tumor cross-sections shows that cavtratin-Figure 1B shows that acute administration of cavtratin signifi-
cantly reduced the extravasation of Evans blue into tumors treated tumors had larger areas of necrosis than did AP-Cav-
X-treated mice, consistent with tumor cell apoptosis leading tocompared to AP-Cav-X-treated animals. However, cavtratin did
not reduce basal vascular permeability in the lungs from treated necrosis (Figures 2C and 2D).
Next we examined potential actions of the peptide in tumors.mice (8.8  1.6 ng, 9.1  1.4 ng, and 8.6  1.8 ng Evans blue/
mg dry tissue, for cavtratin-, AP-Cav-X-, and vehicle-treated Acute administration of biotinylated cavtratin (10 mg/kg, i.p.)
resulted in the appearance of the labeled peptide in the tumormice, respectively; n  4).
To further confirm the decreased tumor blood vessel leaki- mass (Supplemental Figure S1 on Cancer Cell website). Exami-
nation of NOS activity after acute injection of cavtratin (2.5.mg/ness in cavtratin-treated animals, we quantified the ratio of ex-
travascular albumin (bound to Evans blue as an index of fluid kg, i.p.) reduced tumor-derived NOS activity whereas AP-Cav-X
did not (Figure 3A), demonstrating that the peptide could inhibitextravasation) to blood vessels in the tumor microcirculation.
Mice bearing LLC tumors (approximately 2500 mm3) were in- NOS in the tumor. In addition, 7 day treatment with cavtratin,
but not AP-Cav-X, also increased the number of apoptotic cellsjected with a single dose of cavtratin or AP-Cav-X (2.5. mg/kg of
each) followed by intravenous administration of high molecular (indexed by TUNEL staining) in non-necrotic, apparently viable
regions of the tumor (Figure 3B). Finally, we examined the extentweight FITC-dextran (to label the vascular compartment) imaged
in the FITC filter (Lindsberg et al., 1997) and Evans blue (to label of angiogenesis in mice bearing the HepG2 tumors by quantify-
ing PECAM-1-positive blood vessels and PECAM-1 protein lev-the extravasation of plasma protein in the tumor component)
imaged in the TRITC/rhodamine filter (Lindsberg et al., 1997). els (Figures 3C and 3D). As seen in Figure 3C, PECAM-1-positive
profiles were markedly reduced in tumors from cavtratin-treatedThe ratio of rhodamine/FITC fluorescence in multiple tumor sec-
tions was then assessed by optical sectioning of the tumors. mice compared to control, vehicle-, and AP-Cav-X-treated ani-
mals. In addition, the levels of PECAM-1 protein by WesternThe fluorescence ratio of Evans blue to FITC-dextran per tumor
sections allows for a direct quantification of the relative extra- blotting were markedly reduced in cavtratin-treated mice,
whereas VEGF 165 and caveolin-1 levels were identical (Figurevascular albumin content normalized to the density of blood
vessels in the tumor area. As seen in Figure 1C, cavtratin re- 3D). Finally, since both angiogenesis and lymphangiogenesis
may be important for tumor progression, we examined lym-duced the ratio of rhodamine/FITC fluorescence, indicating that
the peptide was blocking vascular leakage in the tumor microcir- phatic vasculature using Flt-4 as a generalized marker for lym-
phatic endothelium (Stacker et al., 2002) in cavtratin- and AP-culation. Representative images of tumor section (Figure 1D)
from cavtratin- and AP-Cav-X-treated mice show that for a simi- Cav-X-treated tumors. As seen in Figure 3E, there were fewer
Flt-4-positive cells in tumors from cavtratin-treated mice. Theselar volume of blood vessels (green FITC-dextran fluorescence),
a strong decrease in Evans blue fluorescence (red filter) in data suggest that cavtratin reduces eNOS activity, decreases
tumor permeability, and triggers apoptosis leading to a loss ofcavtratin-treated animals is observed compared to AP-Cav-
X-treated animals. tumor cells, capillaries, and lymphatic vessels.
In order to investigate if the reduction in tumor growth andTo explore the possibility that interfering with vessel perme-
ability had an effect on tumor growth, we examined the effects increased tumor apoptosis/necrosis produced by cavtratin treat-
ment could be due to a direct antiangiogenic effect (i.e., by blockingof cavtratin administration on tumor progression in mice. The
human hepatocarcinoma cell line HepG2 (5  106 cells per endothelial cell proliferation, migration, and/or organization) in ad-
dition to its effect on vascular leak, we monitored blood vesselmouse) was injected subcutaneously into the flank of NCr Nude
athymic mice and secondly, the mouse-derived LLC cell line formation in a model not associated with vascular leakiness. We
implanted Matrigel plugs filled with basic fibroblast growth factor(1  106 cells per mouse) was dorsally injected to C57BL/6 mice.
When the tumors reached a palpable size, mice were random- (bFGF) on the back of nude mice and monitored vessel assembly
in cavtratin-treated mice (Claffey et al., 2001). The Matrigel modelized into different treatment groups and treated with a single
daily dose of cavtratin (2.5.mg/kg/day) given intraperitoneally of angiogenesis requires stromal cell formation around the plug
followed by massive proteolysis, and the subsequent ingrowth andfor the duration of the study. Controls included noninjected,
vehicle-injected, or a scrambled control peptide AP-Cav-X that reorganization of host endothelial cells with support cells including
fibroblasts and pericytes to form patent vessels. In Figures 4Ahas previously been shown to be ineffective at blocking the NO
synthesis (2.5 mg/kg/day; Bucci et al., 2000). In all groups, and 4B, Matrigel plugs without growth factor showed very few
erythrocyte-filled vessels and cell infiltration, in general (Claffey ettumor progression was monitored as fractional tumor volume
to reflect the increase in tumor mass per animal (Mauceri et al., al., 2001). However, the presence of bFGF triggered a robust
angiogenic response, but cavtratin and AP-Cav-X did not influence1998). Treatment with vehicle, cavtratin, or AP-Cav-X did not
influence normal bodily functions and behavior including weight this process and the vascular profiles were not different amongst
the treatment groups, suggesting that cavtratin does not directlygain, appetite, or grooming behavior. As seen in Figure 2, cav-
tratin significantly reduced tumor progression in immunodefi- suppress angiogenesis, per se.
The effect of cavtratin on endothelial and tumor cell prolifera-cient mice bearing human HepG2 cells tumors and in immuno-
competant mice bearing LLC tumors (Figures 2A and 2B). The tion in culture was also examined. VEGF or serum-induced 3H-
thymidine incorporation into DNA of bovine aortic endothelialfinal tumor volumes were as follows: vehicle: 2802  116 mm3,
cavtratin: 1344  132 mm3, AP-Cav-X: 2794  213 mm3 for cells (BAEC) was not affected by the presence of cavtratin or
AP-Cav-X (10 M) in the media (Supplemental Figure S2 onHepG2 tumors; and vehicle: 3895 618 mm3, cavtratin: 2385
366 mm3, and AP-Cav-X: 3943  689 mm3 for LLC tumors. Cancer Cell website), although this concentration of cavtratin
blocks acetylcholine-induced vasodilation of mouse aortic ringsTreatment with vehicle and the control peptide, AP-Cav-X, were
without effect. These data were repeated in three to four sepa- and NO release from endothelial cells (Bucci et al., 2000). This
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Figure 2. Cavtratin reduces tumor burden
A: Athymic NCr nude mice and B: C57BL/6 mice were injected subcutaneously with either human HepG2 hepatocarcinoma or mouse Lewis lung carcinoma
(LLC) cells, respectively. Tumors were allowed to grow to 400 mm3 for HepG2 and to 100 mm3 for LLC before randomization into treatment groups of
control, vehicle-, cavtratin-, or AP-Cav-X-treated. Mice were given daily intraperitoneal injections of 2.5 mg/kg of peptides. Tumor volume was determined
daily using a caliper and applying the formula (volume  0.52  [width]2  [length]) for approximating the volume of a spheroid. Tumor growth is presented
as means  SEM fraction of the initial tumor volume at day 1 of treatment, n  7–8 mice per group, *p  0.05 when compared to AP-Cav-X treatment.
Representative microscopic images, 4 (top panels) and 40 (bottom panels) objectives of HepG2 (C) and LLC (D) cells tumors stained with hematoxylin
and eosin at the end of peptide treatments. Note the presence of necrotic tissue (black arrow head) and condensed nuclei (white arrow head) in
cavtratin-treated tumors.
result indicates that endothelial cell proliferation is not influ- tumors in wt mice. More importantly, cavtratin reduced tumor
microvascular permeability in wt mice to the same level as thatenced by the cell-permeable peptides. We also monitored if
tumor cell growth was influenced by cavtratin, thus contributing seen in eNOS/ mice and did not reduce permeability further
in tumors implanted into eNOS/mice. To examine if the reduc-to the reduced tumor size and necrosis in cavtratin-treated ani-
mals. HepG2 cells in culture were grown (10% FBS) in the tion in vascular permeability seen in eNOS/ mice influences
tumor progression and if the diminished effect of the peptidepresence of increasing concentrations of cavtratin and AP-Cav-
X (Supplemental Figure S2), and no detectable effect on cell on vascular permeability in eNOS/ translates into a reduction
in tumor size, wt and eNOS/ were implanted with LLC cellsnumber was observed for both peptides at concentrations up
to 10 M. These results indicate that the inhibition of tumor and subgroups of mice treated daily with cavtratin. Tumor pro-
gression is markedly reduced in eNOS/ mice (open circles)growth in these mouse models by cavtratin is unrelated to
growth factor-driven blood vessel formation, per se, or endothe- compared to LLC implanted into wt mice (solid circles; Figure
5B), an effect associated with a reduction in PECAM-1-positivelial cell or tumor cell proliferation.
The above data suggest that cavtratin blocks eNOS-derived vascular profiles in the tumors (6.6%  0.4% versus 3.5% 
0.7* % PECAM-1-positive density (arbitrary units) in LLC tumorsNO release (Bucci et al., 2000) and this mechanism contributes
to the reduction in tumor leakiness and progression. To directly implanted into wt versus eNOS/, *p  0.05; n 4 per group).
Daily administration of cavtratin slowed tumor progression inexamine the role of eNOS in vascular leakage, LLC tumors were
implanted into C57Bl6 (wt) and congenic eNOS/ mice and wt mice (solid triangles) but was less efficacious in eNOS/
mice (open triangles) bearing LLC tumors. These data showallowed to grow to approximately 2000 mm3. Animals were then
treated with either vehicle or a single dose of cavtratin or AP- that the antipermeability and antitumor effects of cavtratin are
markedly reduced in eNOS/ mice.Cav-X (2.5 mg/kg of each). Evans blue was then administrated
to the mice (30 mg/kg, i.v.) and the tumors were subsequently Since there is evidence that caveolin-1 may interact with
the VEGF receptor, Flk-1 (Labrecque et al., 2003), and negativelyperfused with saline and the amount of Evans blue extravasated
into the tumor quantified. As seen in Figure 5A, tumors in regulate c-src, a kinase involved in VEGF-induced permeability
(Eliceiri et al., 1999), we examined if cavtratin can influenceeNOS/ mice are less permeable to Evans blue compared to
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Figure 3. Cavtratin decreases tumor NOS activity, increases apoptosis, and reduces tumor vasculature
A: In vivo treatment with cavtratin (open bars) but not AP-Cav-X (closed bars) reduces tumor NOS activity. eNOS-enriched membranes were prepared
and NOS activity assessed by the conversion of [14C] l-arginine to [14C] l-citrulline in vitro. Membrane extracts were also treated with a NOS inhibitor, L-NAME
(1 mM) to demonstrate the specificity of the activity assay. Data represented pooled samples from three animals per group and are plotted as mean 
SEM.
B: Cavtratin increases the number of TUNEL-positive cells. Mice bearing LLC tumors were treated daily for 7 days with cavtratin or AP-Cav-X and the number
of apoptotic cells assessed histochemically (n  3 tumors per group with 4 sections quantified per tumor).
C: HepG2 tumors sections from untreated control (CT), vehicle-, cavtratin-, and AP-Cav-X-treated NCr nude mice were immunostained for PECAM-1 and
quantified as mean  SEM of the number of blood vessels in three different 20 fields of view of three different sections from tumors of five different animals
per treatment group. *p  0.05 when compared to AP-Cav-X treatment. Inset: Representative sections of PECAM-1 immunohistochemistry from cavtratin-
and AP-Cav-X-treated animals.
D: Western blot analysis for PECAM-1, VEGF 165, and caveolin-1 levels in tumors after 14 day peptide treatment. Protein extracts (50 g) were loaded from
control (CT), cavtratin-, and AP-Cav-X-treated mice bearing HepG2 tumors.
E: Cavtratin reduces Flt-4-positive cells in tumors.
these pathways, in addition to its effects on eNOS. Treatment eNOS is a primary molecular target of the peptide and genetic
loss of eNOS is comparable to eNOS inhibition by cavtratin.of endothelial cells with cavtratin did not block VEGF-induced
Flk-1 autophosphorylation (Figure 6A) or influence the levels Collectively, our data demonstrate that cavtratin inhibits
eNOS-dependent vascular leakage in established tumors byor extent of phosphorylation of c-src (PY416-src) and the c-src
substrate, caveolin-1 (PY14 cav-1, Figure 6B). In contrast, treat- enhancing tumor apoptosis, decreasing tumor angiogenesis,
thereby reducing tumor burden. The mechanisms of how cav-ment of endothelial cells with PP2, a c-src inhibitor, reduced
PY416-src and PY14 caveolin-1 levels. Since cavtratin did not di- tratin reduces vascular leakage most likely relate to the ability
of caveolin-1 to serve as a negative regulator of eNOS functionrectly influence the phosphorylation of c-src or caveolin-1, we
examined the effect of cavtratin on the tyrosine phosphorylation (Bucci et al., 2000; Garcia-Cardena et al., 1997; Michel et al.,
1997), and NO may influence pathways regulating transcellularof VE-cadherin, a key junctional molecule linked to changes in
vascular permeability (Carmeliet et al., 1999). Treatment of hu- and paracellular fluid exchange (Bates et al., 1999; Michel and
Curry, 1999; Schubert et al., 2002). The precise molecular mech-man endothelial cells with cavtratin, AP-Cav-X, or a NOS inhibi-
tor, L-NMMA, had no effect on the tyrosine phosphorylation of anisms of how NO influences tumor and postcapillary fluid ex-
change are not known (i.e., protein kinase G or direct nitrosyla-VE-cadherin. Taken together, these data support the idea that
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Figure 4. Cavtratin does not block angiogenesis,
per se
A: Matrigel plugs containing either vehicle or a
mixture of heparin (23.3 g/ml)/bFGF (0.8 g/ml)
were injected dorsally (right and left center of
back) to NCr nude mice. Control mice (CT) or
mice, treated with cavtratin or AP-Cav-X (2.5
mg/kg/day) were treated for 10 days before Ma-
trigel plug dissection and tissue section staining
with hematoxylin and eosin. Representative sec-
tion from Matrigel containing saline (top row) or
heparin/bFGF (two bottom rows) from control,
cavtratin, and AP-Cav-X show similar cell infiltra-
tion and erythrocyte-filled blood vessels (arrows).
B: Quantity (mean  SEM) of erythrocyte-filled
blood vessels in Matrigel plugs from five different
animals per group in three different 20 fields of
view per section. *p  0.05 when compared to
AP-Cav-X treatment.
tion of junctional proteins). However, the reduced effectiveness in tumor microvasculature, thereby altering the state of tumor
of cavtratin on tumor permeability and progression in eNOS/ vessel permeability which is necessary for tumor cell survival,
mice strongly supports the idea that eNOS is required for the angiogenesis, and tumor progression in these mouse models.
actions of cavtratin; however, we cannot rule out the possibilities More importantly, our study shows that sole intervention at the
of other targets for cavtratin leading to a reduction in permeabil- level of blocking vessel permeability reduces tumor progression,
ity/progression or that the biodistribution of the injected peptide suggesting that targeting tumor microvascular leakiness may
may differ in tumors implanted into wt and eNOS/ mice. An- be a novel, unexploited strategy for antitumor therapy.
other important aspect of our study are data showing that cav-
Experimental procedurestratin is pharmacologically distinct from conventional NOS inhib-
itors since it does not exert significant hemodymanic effects,
Peptidesadministered intravenously (this study) or intraperitoneally (Bucci
Peptides, corresponding to the putative scaffolding domain of caveolin-1et al., 2000). The lack of a hemodynamic effect argues against
(amino acids 82–101; DGIWKASFTTFTVTKYWFYR) or the scrambled control
cavtratin simply reducing blood flow and implies that cavtratin peptide Cav-X (WGIDKAFFTTSTVTYKWFRY), were synthesized as a fusion
targets a fraction of the total eNOS pool that regulates microvas- peptide to the C terminus of the antennapedia (AP) internalization sequence
cular leakage and permeability changes. Thus, we suggest that (RQIKIWFQNRRMKWKK) by standard Fmoc chemistry, purified and ana-
lyzed by reversed-phase high-pressure liquid chromatography and masscavtratin interferes with tumor growth by locally blocking eNOS
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Figure 5. eNOS knockout mice have decreased vascular permeability, tumor growth, and sensitivity to cavtratin
C57BL/6 wild-type (wt) or eNOS/ mice were injected subcutaneously with mouse Lewis lung carcinoma (LLC) cells.
A: As in Figure 1, mice bearing tumors of approximately 2500 mm3 were treated with either cavtratin (2.5 mg/kg; i.p.) or AP-Cav-X (2.5 mg/kg; i.p.) or
untreated (CT) 1 hr before Evans blue administration. Tumors were excised and Evans blue content was quantified spectrophotometrically (n  4). *p 
0.05 when compared to wt. †p  0.05 when compared to CT.
B: Tumor progression of LLC tumors implanted into wt (,) or eNOS/ (,). Mice were either untreated (,) or treated with cavtratin at 2.5 mg/kg;
i.p. (, ). Tumor volume was determined daily using a caliper as in Figure 2 and was plotted as means  SEM of tumor volume (n  9). This experiment
was repeated three times with similar results. Tumors in eNOS/ mice are significantly different from wt mice and cavtratin reduces tumors in wt mice.
spectrometry by the W.M. Keck biotechnology resource center at Yale Uni- were dissolved initially in DMSO and diluted 1000-fold in sterile saline before
in vivo administration (2.5 mg/kg per animal).versity School of Medicine. For detection of the cavtratin peptide in vivo,
biotin followed by an aminohexanoic acid spacer was added to the amino
terminus of the AP fusion peptide. Previous studies in our lab (Bucci et al., Tumor implantation
HepG2 cells were cultured in MEM containing 2 mM L-glutamine and penicil-2000) have shown that at least 100 M of the biotinylated cavtratin was
required to demonstrate an inhibitory effect on vascular relaxation. Peptides lin/streptomycin (Pen/Strep). LLC cells were cultured in DMEM containing
Figure 6. Lack of effect of cavtratin on VEGF re-
ceptor phosphorylation, src signaling, or VE-
cadherin
In A, bovine aortic endothelial cells (BAECs) were
treated with vehicle (CT), cavtratin, or AP-Cav-X
(10 M) for 90 min, stimulated with VEGF (10
ng/ml) for 5 min, and Flk-1 immunoprecipitated.
Lysates were electrophoresed and samples blot-
ted for tyrosine phosphorylated Flk-1 (P-Tyr) and
total Flk-1.
B: BAECs were treated with vehicle (CT), cav-
tratin, AP-Cav-X (10 M each), or the src inhibitor
PP2 (10 M) and the levels of PY416 c-src and PY14
caveolin assessed using phospho-state-specific
antibodies.
In C, human endothelial cells (EA.hy) were
treated with vehicle (CT), cavtratin, AP-Cav-X
(10 M each), or L-NMMA (1 mM) for 60 min and
VE-cadherin immunoprecipitated. Lysates were
electrophoresed and samples blotted for tyro-
sine phosphorylated VE-cadherin (P-tyr) and to-
tal VE-cadherin.
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2 mM L-glutamine and Pen/Strep. Tumor cells were grown to 80% conflu- Tumor permeability
LLC tumors were grown to approximately 2500 mm3 on the back of C57BL/ence on the day of implantation; cells were washed, trypsinized, and resus-
6 mice. Mice were treated for 1 hr with the peptides (2.5 mg/kg; i.p.) andpended in serum free, L-glutamine and Pen/Strep free DMEM. HepG2 cells
were anesthetized (ketamine/xylazine) for the insertion of a polyethylene(5  106 cells in 100 l) were injected subcutaneously in the left flank of
tube in the left jugular vein. Following peptide treatment, Evans blue (30male 6- to 8-week-old NCr nude mice (Taconic, Germantown, New York).
mg/kg) was administered through the catheter for 30 min. Mice were sacri-LLC cells (1  106 cells in 100 l) were subcutaneously injected on the back
ficed and perfused with 0.5% paraformaldehyde for 1 min through the leftof 6- to 8-week-old C57BL/6 mice or congenic eNOS/ mice (Jackson
ventricle. Tumors were excised, dried (60C, 16 hr), and weighed beforeLaboratory). Mice were given 2.5 mg/kg of peptides daily by intraperitoneal
Evans blue extraction in 1 ml of formamide at 55C for 16 hr. Evans blueinjections. Tumor volume was determined daily using a caliper and applying
content was quantified by reading at 610 nm in a spectrophotometer. Forthe formula (volume 0.52 [width]2  [length]) to approximate the volume
imaging of vascular leakage, mice bearing LLC tumors were treated asof a spheroid.
above. Thirty minutes following Evans blue administration, FITC-dextran
(MW: 400 kDa, Sigma) was administered (100 mg/kg in PBS) through theMean arterial pressure measurement
jugular vein catheter. The vascular compartment marker was allowed toC57BL/6 mice were weighed and anesthetized with ketamine hydrochloride
circulate for 1 min before tumor excision. Tumors were fixed for 48 hr in(100 mg/kg) and fastened to a surgical board. Mean arterial pressure (MAP)
10% formalin then sectioned on a vibratome (100 m sections). Sectionswas measured by cannulating the exposed left femoral artery with a PE-10
were mounted onto glass slides and observed using a Zeiss microscope.
(intravascular) catheter joined to PE-50 (extravascular) polyethylene tubing
Images were obtained using the Openlab image analysis software (Improvi-
(Clay Adams, Becton Dickinson, Parsippany, New Jersey), connected to a
sion, Lexington, Massachusetts). Images were acquired using a 10 objec-
H-P pressure transducer (Hewlett-Packard, Andover, Massachusetts). MAP
tive field of view under both the TRITC/rhodamine (Evans blue; 300 ms
was measured acutely and 60 min after bolus injection of cavtratin or AP-
exposure time, 10% gain) and the FITC filters (dextran; 100 ms exposure
Cav-X peptides (2.5 mg/kg) through the jugular vein (n  7 each).
time, 10% gain). Areas of fluorescence were quantified by evaluating the
intensity over background and minimizing the image to a fixed fluorescence
Immunohistochemistry intensity level (30 levels over background for Evans blue and 15 levels for
Tumors were harvested and fixed in 10% formalin for 1–2 hr and transferred FITC). Three images per section were evaluated from three random sections
to 70% ethanol overnight followed by paraffin embedding. These tissues per tumor from at least four different mice per group.
were sectioned for hematoxylin and eosin staining. For immunohistochemi-
cal staining, 3% paraformaldehyde fixed tumor tissues were frozen in OCT eNOS activity assay
after overnight dehydration in 30% sucrose in PBS. Five micrometer sections C57BL/6 mice bearing LLC tumors with approximately 2500 mm3 in size
were stained for PECAM-1 (Pharmingen) or Flt-4 (R&D Systems) and visual- were given either cavtratin or AP-Cav-X (2.5 mg/kg; i.p.) 24 hr and 1 hr
ized using the Vectastain ABC kit (Vector laboratories) followed by incubation before tumors were retrieved by dissection. Tumor tissues were lysed in
with NovaRed substrate (Vector laboratories). For the detection of biotinyl- lysis buffer containing 50 mM Tris-HCl (pH 7.4), 0.1 mM EDTA, 0.1 mM EGTA,
ated cavtratin, 10 m tumor sections were stained for Alexa 488 conjugated 20 mM NaF, 1 mM Na4P2O7, 0.3 mg/ml Pefabloc SC, 1 g/ml leupeptin, 1
Steptavidin and counterstained with DAPI. g/ml aprotinin, 2 g/ml pepstatin A, and 1 mM vanadate. After pulverizing
tumor tissues using rotor-stator homogenizer (PowerGen 125, Fisher Scientific),
TUNEL assay homogenized samples were centrifuged at 1000 rpm for 10 min to remove
After 7 days of peptide treatment, C57BL/6 mice bearing LLC tumors were unbroken cells and tissue. The supernatant was ultracentrifuged at 100,000 
sacrificed and tumor tissue processed for paraffin embedding as mentioned g for 1 hr to separate membrane and cytosolic fractions. The eNOS-enriched
above. Five micrometer sections were deparaffinized and digested with 20 membrane fractions were resuspended by dounce homogenization (20 strokes)
in the same lysis buffer as above mentioned. eNOS activity assay wasug/ml of Proteinase K for 15 min. After quenching endogenous peroxidase
performed by conversion of [14C] l-arginine to [14C] l-citrulline. Samples wereactivity using 3% H2O2 for 5 min, these sections were incubated with ApoTag
first assayed to normalize protein concentration. Approximately 800 g ofTUNEL (Intergen) reaction solution for 1 hr at 37C. TUNEL-positive nuclei
total protein was used per assay reaction and was diluted in a total volumewere then processed for immunoperoxidase staining with anti-digoxigenin
of 100 l of activity assay buffer containing 50 mM Tris-HCl (pH 7.5), 0.1 mMantibody and visualized by NovaRed substrate. The percent of TUNEL-positive
EDTA, 0.1 mM EGTA, 100 nM calmodulin (Sigma), 1 mM NADPH (Sigma),nuclei was quantified using Scion Image 1.62c (Scion Corporation) and normal-
15 M BH4 (6R-tetrahydro-l-biopterin, Sigma), 8.6 M L-arginine (Sigma),ized to total pixel density of non-necrotic areas that were quantified.
1.4 M [14C] l-arginine (348 mCi/mmol), and 2.5 mM CaCl2 (Sigma) plus or
minus 1 mM N	-nitro-l-arginine methyl ester (L-NAME). All reaction samplesEndothelial cell proliferation
were kept on ice until incubation at 37C for 15 min. The reaction wasBovine aortic endothelial cells (BAECs) were cultured in DMEM containing
stopped by adding 1 ml of ice cold stop buffer containing 20 mM HEPES10% FBS (HyClone), containing 2 mM L-glutamine and Pen/Strep. Cells
(pH 5.5), 2 mM EDTA, and 2 mM EGTA to each sample. The samples werewere plated in 96 well plates (5000 cells/well) and serum starved for 24 hr.
then passed through Dowex AG50WX8 cation exchange resin and the flowPeptides were added 1 hr before VEGF or 5% FBS stimulation. Growth
through was counted on a liquid scintillation analyzer.
factor-stimulated BAEC proliferation was monitored for 20 hr, [3H]-thymidine
(0.5 Ci/well) was present for the last 4 hr. Nuclear DNA was extracted using
Immunoprecipitation and Western blotting
a Brandel Harvester 96 onto Whatman GF/B paper filter mats. The filters
For detection of total PECAM and VEGF 165 in tumors, HepG2 tumors at
were assayed for 3H using a Beckman model LS6000IC liquid scintillation
the end of the 14 day peptide treatment were excised and lysed in lysis
counter. buffer containing 50 mM Tris-HCl (pH 7.4), 100 mM NaCl, 0.1 mM EGTA,
0.1 mM EDTA, 1% Triton X-100, 1 mM sodium orthovanadate, 20 mM NaF,
Miles assay 1 mM Na4P2O7, 1 mM Pefabloc SC, and protease inhibitor cocktail (Roche
Male Swiss mice (CD-1, 25–30 grams) were pretreated for 45 min with Diagnostics). Insoluble proteins were removed by centrifugation at 13,000
vehicle, cavtratin, or AP-Cav-X (2.5 mg/kg i.p. each). Animals were anesthe- rpm for 10 min at 4C. Supernatants were boiled in SDS sample buffer
tized with ketamine/xylazine, and a catheter was introduced into the left and separated by SDS-PAGE followed by Western blotting for PECAM-1
jugular vein for administration of Evans blue (30 mg/kg; Sigma). One minute (Pharmingen), VEGF 165 (Santa Cruz Biotechnologies), and caveolin-1 (Cell
following the administration of the dye, VEGF (30 ng) or saline was injected Signaling) for loading control. BAECs or EA.hy cells were grown to confluency
intradermally (30 l total) into the right and left dorsal ear skin, respectively. and serum starved (16 hr) before treatment with either 10 M of cavtra-
After 30 min, animals were sacrificed and ears were removed, blotted dry, tin, AP-Cav-X (90 min), PP2 (30 min), or 1 mM NG-monomethyl-l-arginine
and weighed. Evans blue content of the ear was evaluated by extraction (L-NMMA) for 45 min followed by 10 ng/ml of VEGF for 5 min (BAEC only).
with 500 l of formamide for 24 hr at 55C and measured spectrophotometri- All cells were washed twice with cold PBS and solubilized with the same
lysis buffer as above. Insoluble proteins were removed by centrifugation atcally at 610 nm.
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D.A. (1999). Selective requirement for Src kinases during VEGF-induced13,000 rpm for 10 min at 4C. Supernatants were incubated with either Flk-1
angiogenesis and vascular permeability. Mol. Cell 4, 915–924.(for BAECs) or VE-Cadherin (for EA.hy cells) (Santa Cruz Biotechnology)
antibody for 2 hr at 4C. Protein A Sepharose (Sigma) was then added and Fukumura, D., Gohongi, T., Kadambi, A., Izumi, Y., Ang, J., Yun, C.O., Buerk,
incubated for an additional hour. Immune complexes were precipitated by D.G., Huang, P.L., and Jain, R.K. (2001). Predominant role of endothelial
centrifugation, washed three times with lysis buffer, boiled in SDS sample nitric oxide synthase in vascular endothelial growth factor-induced angiogen-
buffer. Samples were then resolved on SDS-PAGE and Western blotted esis and vascular permeability. Proc. Natl. Acad. Sci. USA 98, 2604–2609.
for phosphotyrosine (4G10, Upstate), Flk-1, phospho-Src (P-Tyr 416, Cell
Garcia-Cardena, G., Martasek, P., Masters, B.S., Skidd, P.M., Couet, J., Li,
Signaling), total Src (Upstate), phospho-caveolin-1 (P-Tyr 14, Cell Signaling), S., Lisanti, M.P., and Sessa, W.C. (1997). Dissecting the interaction between
total caveolin-1 (Santa Cruz), or VE-cadherin. nitric oxide synthase (NOS) and caveolin. Functional significance of the nos
caveolin binding domain in vivo. J. Biol. Chem. 272, 25437–25440.
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